Michael Aberman

General Partner

2024 - Current

Board Member

2021

Stealth Biotech

Board Member

2020

Provide strategic, business development, and financing advice to CEO and CSO of UNP, an emerging biotech company that is unlocking the potential of macrocycle drug discovery through data science and massively parallel synthesis.

Business Advisor

2020 - 2024

Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients. Pipeline projects include HIV, PML/JCV, HSV, and COVID-19 Treatment & Prevention. https://www.Excision.Bio/

Board Member

2020 - 2024

Rover Diagnostic’s Lightspeed is a potentially best-in-class, cost-effective, point-of-care, COVID-19 test that is saliva-based, CLIA-waived, and uses the gold-standard rtPCR to deliver results in under 15 minutes. It was accepted in the NIH RADx program to accelerate availability and capacity for COVID testing.

SeniorAdvisor

2020 - 2022

Provide corporate strategy, business development, and financing advice to the CEO and CBO of Immunai, an innovate biotech company that is comprehensively mapping the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes.

President and CEO

2017 - 2019

Senior Vice President, Strategy and Investor Relations

2010 - 2017

Biotech Analyst

2006 - 2010

Biotech Analyst

2004 - 2006